Amicus Therapeutics Inc (FOLD)vsInsmed Inc (INSM)
FOLD
Amicus Therapeutics Inc
$14.43
+0.14%
HEALTHCARE · Cap: $4.52B
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Amicus Therapeutics Inc generates 5% more annual revenue ($634.21M vs $606.42M). INSM leads profitability with a -2.1% profit margin vs -4.3%. INSM earns a higher WallStSmart Score of 39/100 (F).
FOLD
Avoid30
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 23.7% year-over-year
No standout strengths identified
Areas to Watch
Trading at 16.4x book value
Elevated debt levels
Weak financial health signals
ROE of -11.6% — below average capital efficiency
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : FOLD
The strongest argument for FOLD centers on Revenue Growth. Revenue growth of 23.7% demonstrates continued momentum.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : FOLD
The primary concerns for FOLD are Price/Book, Debt/Equity, Piotroski F-Score. Debt-to-equity of 1.61 is elevated, increasing financial risk.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
FOLD profiles as a growth stock while INSM is a turnaround play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
FOLD is growing revenue faster at 23.7% — sustainability is the question.
FOLD generates stronger free cash flow (16M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 30/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amicus Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing and delivering drugs for people living with rare metabolic diseases. The company is headquartered in Philadelphia, Pennsylvania.
Visit Website →Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?